management comp...--in the real world pay is based typically on a combination of what others in similar positions make and performance... So to fairly look at NPH key management pay you have to look at (do DD) what other similar healthcare company key personal make at other companies... The fact that NPH is not at break even yet means little and in fact a huge percentage of bio companies are not at break even and check their CEO pay... So it may be a good idea to check into this , for yourself if unsure, before making coments IMO... and also factor in the stellar performance of management to date...
-stock options are not great to align management with long term shareholders...they promote a trader mentality...
-NPH is running a lean ship to execute the plan and does not have the capacity for any cash payment increases ...likely for over a year at least...
-the best way to pay key management, and benefit long term shareholders, is to have management that are incentivized to perform to the benefit of the comany (ie sales and capital structure governance) and have the managments interests aligned with long term shareholders through them owning sizeable non-tradable common shares...